Er tumor cell injection, similar osteolytic lesions, characteristic for 143-B cell-derived

Er tumor cell injection, similar osteolytic lesions, characteristic for 143-B cell-derived tumors, were recognized by X-ray in all three groups of mice (Figure 3A). Somehow unexpectedly, caliper measurements of the volume of the tumor legs over time revealed growth of intratibial primary tumors to a significantly (p,0.001) larger final size at sacrifice on experimental day 20 in mice injected with 143-B 6R-Tetrahydro-L-biopterin dihydrochloride cost shCD44 cells (108 6 14 mm3, n = 9) than in animals that received 143-B EV cells (39 6 6 mm3, n = 9) (Figure 3B). The mean size of tumors developing in mice injected with 143-B Ctrl shRNA cells (65 6 25 mm3, n = 6) was intermediate, but not significantly different from that in mice injected with 143-B shCD44 or with 143-B EV cells, most probably due to the fact that Ctrl shRNA group consisted of only 6 animals that exhibited greater heterogeneity in tumor size than the other experimental groups. Two of the 6 mice of 143-B Ctrl group, in particular, developed remarkably larger primary tumors thanthe other 4 mice of this group and all mice in the 143-B EV group that were similar in size. Interestingly, beside the described larger size of 143-B shCD44 compared to 143-B EV and 143-B Ctrl shRNA cell-derived primary tumors, the mean number of metastatic lesions on lung surfaces at sacrifice, detected by X-gal staining, were also found significantly increased 2-fold (p,0.05) and 2.4-fold (p,0.05) in mice with 143-B shCD44 cell-derived tumors compared the numbers counted on the lungs of animals injected with 143-B EV or 143-B Ctrl shRNA cells, respectively (Figure 3C, D). In view of the discrepant malignant properties of 143-B shCD44 cells in vitro and in vivo, we assessed the expression of immunoreactive CD44 by immunohistochemistry with Hermes3 antibodies in primary tumor tissue and lung metastases derived from 143-B shCD44 cells and compared it with 143-B EV and 143-B Ctrl shRNA cell-derived tumors. This analysis demonstrated thatCD44 Docosahexaenoyl ethanolamide manufacturer Silencing Promotes Osteosarcoma MetastasisFigure 4. Ex-vivo immunohistochemical analysis of shRNA mediated CD44 silencing in 143-B-lacZ OS cell-derived intratibial primary tumors and pulmonary metastases. Robust expression of immunoreactive CD44 observed in primary tumor (PT) tissue and pulmonary metastases (PM) derived from 143-B EV (EV) (A,G) and 143-B Ctrl shRNA (Ctrl shRNA) cells (B,H) was found suppressed in tumor tissue (C) and lung metastases (I) derived from 143-B shCD44 (shCD44) cells. Immunohistochemically detectable HA in PT (panels D-F) was not affected by CD44 silencing. The figure shows images of representative 6 mm paraffin sections with cell nuclei counterstained with hematoxylin. Bars, 100 mm. doi:10.1371/journal.pone.0060329.gCD44 silencing was maintained in vivo in 143-B shCD44 cells (Figure 4C and I). The content of HA in the extracellular matrix of primary tumors, on the other hand, was indistinguishable in 143-B shCD44, -EV and -Ctrl shRNA cell-derived tumors, indicating that the levels of expression of CD44 gene products in 143-B cells did not affect extracellular HA deposition (Figure 4D-F). Interestingly, nuclear Ki67 immunostaining of proliferating tumor cells on primary tumor and lung paraffin sections showed a specific structure of primary tumors and lung metastases in mice bearing tumors depleted of CD44. 143-B shCD44 cells appeared to be in much looser contact in primary tumors and metastases than 143-B EV and 143-B Ctrl shRNA cells that formed remarkably denser malignant tissue than.Er tumor cell injection, similar osteolytic lesions, characteristic for 143-B cell-derived tumors, were recognized by X-ray in all three groups of mice (Figure 3A). Somehow unexpectedly, caliper measurements of the volume of the tumor legs over time revealed growth of intratibial primary tumors to a significantly (p,0.001) larger final size at sacrifice on experimental day 20 in mice injected with 143-B shCD44 cells (108 6 14 mm3, n = 9) than in animals that received 143-B EV cells (39 6 6 mm3, n = 9) (Figure 3B). The mean size of tumors developing in mice injected with 143-B Ctrl shRNA cells (65 6 25 mm3, n = 6) was intermediate, but not significantly different from that in mice injected with 143-B shCD44 or with 143-B EV cells, most probably due to the fact that Ctrl shRNA group consisted of only 6 animals that exhibited greater heterogeneity in tumor size than the other experimental groups. Two of the 6 mice of 143-B Ctrl group, in particular, developed remarkably larger primary tumors thanthe other 4 mice of this group and all mice in the 143-B EV group that were similar in size. Interestingly, beside the described larger size of 143-B shCD44 compared to 143-B EV and 143-B Ctrl shRNA cell-derived primary tumors, the mean number of metastatic lesions on lung surfaces at sacrifice, detected by X-gal staining, were also found significantly increased 2-fold (p,0.05) and 2.4-fold (p,0.05) in mice with 143-B shCD44 cell-derived tumors compared the numbers counted on the lungs of animals injected with 143-B EV or 143-B Ctrl shRNA cells, respectively (Figure 3C, D). In view of the discrepant malignant properties of 143-B shCD44 cells in vitro and in vivo, we assessed the expression of immunoreactive CD44 by immunohistochemistry with Hermes3 antibodies in primary tumor tissue and lung metastases derived from 143-B shCD44 cells and compared it with 143-B EV and 143-B Ctrl shRNA cell-derived tumors. This analysis demonstrated thatCD44 Silencing Promotes Osteosarcoma MetastasisFigure 4. Ex-vivo immunohistochemical analysis of shRNA mediated CD44 silencing in 143-B-lacZ OS cell-derived intratibial primary tumors and pulmonary metastases. Robust expression of immunoreactive CD44 observed in primary tumor (PT) tissue and pulmonary metastases (PM) derived from 143-B EV (EV) (A,G) and 143-B Ctrl shRNA (Ctrl shRNA) cells (B,H) was found suppressed in tumor tissue (C) and lung metastases (I) derived from 143-B shCD44 (shCD44) cells. Immunohistochemically detectable HA in PT (panels D-F) was not affected by CD44 silencing. The figure shows images of representative 6 mm paraffin sections with cell nuclei counterstained with hematoxylin. Bars, 100 mm. doi:10.1371/journal.pone.0060329.gCD44 silencing was maintained in vivo in 143-B shCD44 cells (Figure 4C and I). The content of HA in the extracellular matrix of primary tumors, on the other hand, was indistinguishable in 143-B shCD44, -EV and -Ctrl shRNA cell-derived tumors, indicating that the levels of expression of CD44 gene products in 143-B cells did not affect extracellular HA deposition (Figure 4D-F). Interestingly, nuclear Ki67 immunostaining of proliferating tumor cells on primary tumor and lung paraffin sections showed a specific structure of primary tumors and lung metastases in mice bearing tumors depleted of CD44. 143-B shCD44 cells appeared to be in much looser contact in primary tumors and metastases than 143-B EV and 143-B Ctrl shRNA cells that formed remarkably denser malignant tissue than.